株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

マイコプラズマ検査の世界市場 2019年:製品 (器具・キット&試薬・サービス)・用途 (細胞株・ウイルス・EPC)・技術 (PCR・ELISA・直接検査)・エンドユーザー別

Mycoplasma Testing Market by Products (Instruments, Kits & Reagents, Services), Application (Cell Line, Virus, End of Production Cells), Technology (PCR, ELISA, Direct Assay), End User (Cell Banks, Pharmaceutical Companies) - Global Forecast to 2019

発行 MarketsandMarkets 商品コード 330368
出版日 ページ情報 英文 180 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.81円で換算しております。
Back to Top
マイコプラズマ検査の世界市場 2019年:製品 (器具・キット&試薬・サービス)・用途 (細胞株・ウイルス・EPC)・技術 (PCR・ELISA・直接検査)・エンドユーザー別 Mycoplasma Testing Market by Products (Instruments, Kits & Reagents, Services), Application (Cell Line, Virus, End of Production Cells), Technology (PCR, ELISA, Direct Assay), End User (Cell Banks, Pharmaceutical Companies) - Global Forecast to 2019
出版日: 2015年05月11日 ページ情報: 英文 180 Pages
概要

世界のマイコプラズマ検査市場は2014年から2019年にかけて12.51%のCAGRで推移し、2014年の3億4029万ドルから2019年には6億1349万ドルの規模に成長すると予測されています。

当レポートでは、世界のマイコプラズマ検査の市場について調査し、マイコプラズマ検査の概要と産業構造、製品・技術・用途・エンドユーザー別の市場分析および市場成長予測、市場成長への各種影響因子と市場機会の分析、地域および主要国別の動向、競合環境と市場シェア、主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

  • 高成長率のマイコプラズマ検査市場
  • ライフサイクル分析:地域別

第5章 市場概要

  • イントロダクション
  • 市場区分
    • 製品別
    • 技術別
    • 用途別
    • エンドユーザー別
  • 市場力学
    • 成長推進因子
    • 成長阻害因子
    • 市場機会

第6章 産業分析

  • イントロダクション
  • ポーターのファイブフォース分析
  • 戦略的ベンチマーキング
  • サプライチェーン分析

第7章 マイコプラズマ検査市場:製品別

  • イントロダクション
  • キット&試薬
    • PCRアッセイ
    • 核酸検出キット
    • 除去キット・試薬
    • 染色液
    • スタンダート&コントロール
    • その他のキット&試薬
  • 器具
  • サービス

第8章 マイコプラズマ検査市場:技術別

  • イントロダクション
  • PCR
  • Elisa
  • 直接検査
  • 間接検査
  • DNA染色
  • 微生物培養法
  • 酵素的方法

第9章 マイコプラズマ検査市場:用途別

  • イントロダクション
  • 細胞株検査
  • ウイルス検査
  • EPC (End of Production Cells) 検査
  • その他

第10章 マイコプラズマ検査市場:エンドユーザー別

  • イントロダクション
  • 医薬品・バイオテクノロジー企業
  • CRO
  • 学術研究機関
  • 細胞バンク
  • その他

第11章 地域分析

  • イントロダクション
  • 北米
    • 米国
    • カナダ
  • 欧州
  • アジア
  • その他の地域

第12章 競合環境

  • イントロダクション
  • 市場シェア分析
  • 競合状況・動向
    • 合意・提携・協力
    • 拡張
    • 買収
    • 新製品・サービスの投入
    • その他の戦略

第13章 企業プロファイル

  • イントロダクション
  • Charles River Laboratories International, Inc.
  • Lonza Group Ltd.
  • Merck & Co., Inc.
  • Sigma-Aldrich Corporation
  • Thermo Fisher Scientific, Inc.
  • American Type Culture Collection
  • Biological Industries Israel Beit Haemek Ltd.
  • Bionique Testing Laboratories, Inc.
  • Invivogen
  • Promo Cell GMBH
    • 事業概要
    • 製品ポートフォリオ
    • 近年の発展動向
    • MNMの見解、など

第14章 付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: BT 3371

The global mycoplasma testing market is expected to reach $613.49 million by 2019 from $340.29 million in 2014, growing at a CAGR of 12.51% between 2014 and 2019. The mycoplasma testing product segments included in this report are instruments, kits & reagents, and services. The kits & reagents segment is further divided on the basis of type into stains, elimination kits, PCR assays, nucleic acid detection kits, standards & controls and other kits & reagents. The technology segments included are microbial culture techniques, DNA staining, PCR, ELISA, direct assay, indirect assay and enzymatic methods. On the basis of applications, the report is segmented into cell line testing, virus testing, end of production cells testing and other applications. The cell line testing applications had the largest share of the mycoplasma testing market in 2014. The cell line testing application is expected to be one of the fastest growing applications between 2014 and 2019.

The geographic segments included in this report are North America, Europe, Asia and Rest of the World (RoW). The geographic analysis reveals that North America accounted for the largest share in the global mycoplasma testing market in 2014. Asia regional segment, on the other hand, is expected to register a faster growth from 2014 to 2019, due to the increasing demand for mycoplasma testing and drug discovery and research from this region.

The key driver for this market is increased research funding by government. Furthermore, growing biotechnology and pharmaceutical companies to increase R&D activities and innovations in life science research and will aid the growth of the global mycoplasma testing market.

A combination of bottom-up and top-down approaches were used to calculate the market sizes and growth rates of the global mycoplasma testing market and its sub-segments. Secondary information was used to identify the overall revenues, geographic reach, and product portfolios of the market players. Estimates of their mycoplasma testing product segment revenues were validated through primary interviews. Primary interviews with key opinion leaders were also used to determine percentage shares of each sub segment and the relative differences in the growth rates.

The report provides qualitative insights about key market shares, growth rates, and market drivers for all important sub segments. It maps the market sizes and growth rates of each sub segment and identifies the segments poised for rapid growth in each of the geographic segments. The report also includes company profiles of the market leaders. These company profiles include financial performances, product portfolios, and market developments for each company. The report also provides a competitive landscape of the mycoplasma testing market. The competitive landscape covers the growth strategies adopted by the industry players over the last four years. It also includes analysis of industry developments like expansions, agreements and partnerships, mergers and acquisitions and new product launches.

Reasons to Buy the Report:

The report will enable both established firms and new entrants to gauge the pulse of the market and help them make important strategic growth decisions.

The report provides insights on the following:

  • Product Development: Product portfolios of the top players in the mycoplasma testing market.
  • Competitive Assessment: In-depth assessment of the market shares, strategies, geographic and business segments, and product portfolios of the leading players in the mycoplasma testing market.
  • Market Development: Comprehensive information about the lucrative emerging markets. The report analyzes the market for various mycoplasma testing products across geographies.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. MARKET SIZE ESTIMATION
  • 2.2. MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.3. MARKET SHARE ESTIMATION
    • 2.3.1. KEY DATA FROM SECONDARY SOURCES
    • 2.3.2. KEY DATA FROM PRIMARY SOURCES
    • 2.3.3. ASSUMPTIONS

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

  • 4.1. MYCOPLASMA TESTING MARKET TO GROW AT A RATE OF 12.51% IN THE FORECAST PERIOD
  • 4.2. LIFE CYCLE ANALYSIS, BY REGION

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET SEGMENTATION
    • 5.2.1. MYCOPLASMA TESTING MARKET, BY PRODUCT
    • 5.2.2. MYCOPLASMA TESTING MARKET, BY TECHNOLOGY
    • 5.2.3. MYCOPLASMA TESTING MARKET, BY APPLICATION
    • 5.2.4. MYCOPLASMA TESTING MARKET, BY END USER
  • 5.3. MARKET DYNAMICS
    • 5.3.1. DRIVERS
      • 5.3.1.1. Rapid growth in the pharmaceutical and biotechnology industries
      • 5.3.1.2. Strong trend of R&D investments in life sciences
      • 5.3.1.3. Increasing government support for pharmaceutical and biotechnology industries
    • 5.3.2. RESTRAINTS
      • 5.3.2.1. High degree of consolidation acts as an entry barrier for new entrants
      • 5.3.2.2. Stringent regulatory frameworks and time-consuming approval processes
    • 5.3.3. OPPORTUNITIES
      • 5.3.3.1. Increasing pharmaceutical outsourcing

6. INDUSTRY INSIGHTS

  • 6.1. INTRODUCTION
  • 6.2. PORTER'S FIVE FORCES ANALYSIS
    • 6.2.1. THREAT OF NEW ENTRANTS
    • 6.2.2. THREAT OF SUBSTITUTES
    • 6.2.3. BARGAINING POWER OF BUYERS
    • 6.2.4. BARGAINING POWER OF SUPPLIERS
    • 6.2.5. COMPETITIVE RIVALRY AMONG EXISTING PLAYERS
  • 6.3. STRATEGIC BENCHMARKING
    • 6.3.1. AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS
  • 6.4. SUPPLY CHAIN ANALYSIS
    • 6.4.1. KEY INFLUENCERS

7. MYCOPLASMA TESTING MARKET, BY PRODUCT

  • 7.1. INTRODUCTION
  • 7.2. KITS & REAGENTS
    • 7.2.1. PCR ASSAYS
    • 7.2.2. NUCLEIC ACID DETECTION KITS
    • 7.2.3. ELIMINATION KITS& REAGENTS
    • 7.2.4. STAINS
    • 7.2.5. STANDARDS & CONTROLS
    • 7.2.6. OTHER KITS & REAGENTS
  • 7.3. INSTRUMENTS
  • 7.4. SERVICES

8. MYCOPLASMA TESTING MARKET, BY TECHNOLOGY

  • 8.1. INTRODUCTION
  • 8.2. PCR
  • 8.3. ELISA
  • 8.4. DIRECT ASSAY
  • 8.5. INDIRECT ASSAY
  • 8.6. DNA STAINING
  • 8.7. MICROBIAL CULTURE TECHNIQUES
  • 8.8. ENZYMATIC METHODS

9. MYCOPLASMA TESTING MARKET, BY APPLICATION

  • 9.1. INTRODUCTION
  • 9.2. CELL LINE TESTING
  • 9.3. VIRUS TESTING
  • 9.4. END OF PRODUCTION CELLS TESTING
  • 9.5. OTHER APPLICATIONS

10. MYCOPLASMA TESTING MARKET, BY END USER

  • 10.1. INTRODUCTION
  • 10.2. PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
  • 10.3. CONTRACT RESEARCH ORGANIZATIONS
  • 10.4. ACADEMIC RESEARCH INSTITUTES
  • 10.5. CELL BANKS
  • 10.6. OTHER END USERS

11. GEOGRAPHIC ANALYSIS

  • 11.1. INTRODUCTION
  • 11.2. NORTH AMERICA
    • 11.2.1. U.S.
    • 11.2.2. CANADA
  • 11.3. EUROPE
  • 11.4. ASIA
  • 11.5. REST OF THE WORLD (ROW)

12. COMPETITIVE LANDSCAPE

  • 12.1. INTRODUCTION
  • 12.2. MARKET SHARE ANALYSIS, MYCOPLASMA TESTING MARKET
  • 12.3. COMPETITIVE SITUATION AND TRENDS
    • 12.3.1. AGREEMENTS, COLLABORATIONS AND PARTNERSHIPS
    • 12.3.2. EXPANSIONS
    • 12.3.3. ACQUISITIONS
    • 12.3.4. NEW PRODUCT AND SERVICE LAUNCHES
    • 12.3.5. OTHER STRATEGIES

13. COMPANY PROFILES (Overview, Products and Services, Financials, Strategy & Development)*

  • 13.1. INTRODUCTION
  • 13.2. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
  • 13.3. LONZA GROUP LTD.
  • 13.4. MERCK KGAA
  • 13.5. SIGMA-ALDRICH CORPORATION
  • 13.6. THERMO FISHER SCIENTIFIC, INC.
  • 13.7. AMERICAN TYPE CULTURE COLLECTION
  • 13.8. BIOLOGICAL INDUSTRIES ISRAEL BEIT HAEMEK LTD.
  • 13.9. BIONIQUE TESTING LABORATORIES, INC.
  • 13.10. INVIVOGEN
  • 13.11. PROMO CELL GMBH

*Details on Overview, Products and Services, Financials, Strategy & Development might not be Captured in case of Unlisted Companies.

14. APPENDIX

  • 14.1. INSIGHTS OF INDUSTRY EXPERTS
  • 14.2. DISCUSSION GUIDE
  • 14.3. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 14.4. AVAILABLE CUSTOMIZATIONS
  • 14.5. RELATED REPORTS

LIST OF TABLES

  • TABLE 1: MYCOPLASMA TESTING MARKET SUMMARY
  • TABLE 2: RAPID GROWTH IN THE PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRIES IS PROPELLING THE GROWTH OF THE MYCOPLASMA TESTING MARKET
  • TABLE 3: HIGH DEGREE OF CONSOLIDATION ACTS AS THE MAJOR ENTRY BARRIER FOR NEW ENTRANTS
  • TABLE 4: INCREASING PHARMACEUTICAL OUTSOURCING IS PAVING NEW GROWTH AVENUES FOR PLAYERS IN THE MYCOPLASMA TESTING MARKET
  • TABLE 5: MARKET DEVELOPMENTS BETWEEN 2011 AND 2015
  • TABLE 6: MYCOPLASMA TESTING MARKET SIZE, BY PRODUCT, 2012-2019 (USD MILLION)
  • TABLE 7: MYCOPLASMA TESTING KITS & REAGENTS MARKET SIZE, BY TYPE, 2012-2019 (USD MILLION)
  • TABLE 8: MYCOPLASMA TESTING KITS & REAGENTS MARKET SIZE, BY REGION, 2012-2019 (USD MILLION)
  • TABLE 9: PCR ASSAYS MARKET SIZE, BY REGION, 2012-2019 (USD MILLION)
  • TABLE 10: NUCLEIC ACID DETECTION KITS MARKET SIZE, BY REGION, 2012-2019 (USD MILLION)
  • TABLE 11: NORTH AMERICA COMMANDED THE LARGEST SHARE OF ELIMINATIONS KITS & REAGENTS SEGMENT IN 2014
  • TABLE 12: ELIMINATION KITS & REAGENTS MARKET SIZE, BY REGION, 2012-2019 (USD MILLION)
  • TABLE 13: MYCOPLASMA TESTING STAINS MARKET SIZE, BY REGION, 2012-2019 (USD MILLION)
  • TABLE 14: STANDARDS & CONTROLS MARKET SIZE, BY REGION, 2012-2019 (USD MILLION)
  • TABLE 15: OTHER KITS & REAGENTS MARKET SIZE, BY REGION, 2012-2019 (USD MILLION)
  • TABLE 16: MYCOPLASMA TESTING INSTRUMENTS MARKET SIZE, BY REGION, 2012-2019 (USD MILLION)
  • TABLE 17: MYCOPLASMA TESTING SERVICES MARKET SIZE, BY REGION, 2012-2019 (USD MILLION)
  • TABLE 18: MYCOPLASMA TESTING MARKET SIZE, BY TECHNOLOGY, 2012-2019 (USD MILLION)
  • TABLE 19: PCR METHOD MARKET SIZE, BY REGION, 2012-2019 (USD MILLION)
  • TABLE 20: ELISA METHOD MARKET SIZE, BY REGION, 2012-2019 (USD MILLION)
  • TABLE 21: DIRECT ASSAY MARKET SIZE, BY REGION, 2012-2019 (USD MILLION)
  • TABLE 22: INDIRECT ASSAY MARKET SIZE, BY REGION, 2012-2019 (USD MILLION)
  • TABLE 23: NORTH AMERICA ACCOUNTED FOR THE LARGEST SHARE OF THE DNA STAINING TECHNOLOGY SEGMENT IN 2014
  • TABLE 24: DNA STAINING MARKET SIZE, BY REGION, 2012-2019 (USD MILLION)
  • TABLE 25: MICROBIAL CULTURE TECHNIQUES MARKET SIZE, BY REGION, 2012-2019 (USD MILLION)
  • TABLE 26: ENZYMATIC METHODS MARKET SIZE, BY REGION, 2012-2019 (USD MILLION)
  • TABLE 27: MYCOPLASMA TESTING MARKET SIZE, BY APPLICATION, 2012-2019 (USD MILLION)
  • TABLE 28: MYCOPLASMA TESTING MARKET SIZE FOR CELL LINE TESTING, BY REGION, 2012-2019 (USD MILLION)
  • TABLE 29: MYCOPLASMA TESTING MARKET SIZE FOR VIRUS TESTING, BY REGION, 2012-2019 (USD MILLION)
  • TABLE 30: MYCOPLASMA TESTING MARKET SIZE FOR END OF PRODUCTION CELLS TESTING APPLICATIONS, BY REGION, 2012-2019 (USD MILLION)
  • TABLE 31: MYCOPLASMA TESTING MARKET SIZE FOR OTHER APPLICATIONS, BY REGION, 2012-2019 (USD MILLION)
  • TABLE 32: MYCOPLASMA TESTING MARKET SIZE, BY END USER, 2012-2019 (USD MILLION)
  • TABLE 33: MYCOPLASMA TESTING MARKET SIZE FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2012-2019 (USD MILLION)
  • TABLE 34: MYCOPLASMA TESTING MARKET SIZE FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2012-2019 (USD MILLION)
  • TABLE 35: MYCOPLASMA TESTING MARKET SIZE FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2012-2019 (USD MILLION)
  • TABLE 36: MYCOPLASMA TESTING MARKET SIZE FOR CELL BANKS, BY REGION, 2012-2019 (USD MILLION)
  • TABLE 37: MYCOPLASMA TESTING MARKET SIZE FOR OTHER END USERS, BY REGION, 2012-2019 (USD MILLION)
  • TABLE 38: MYCOPLASMA TESTING MARKET SIZE, BY REGION, 2012-2019 (USD MILLION)
  • TABLE 39: NORTH AMERICA: MYCOPLASMA TESTING MARKET SIZE, BY COUNTRY, 2012-2019 (USD MILLION)
  • TABLE 40: NORTH AMERICA: MYCOPLASMA TESTING MARKET SIZE, BY PRODUCT, 2012-2019 (USD MILLION)
  • TABLE 41: NORTH AMERICA: KITS & REAGENTS MARKET SIZE, BY TYPE, 2012-2019 (USD MILLION)
  • TABLE 42: NORTH AMERICA: MYCOPLASMA TESTING MARKET SIZE, BY TECHNOLOGY, 2012-2019 (USD MILLION)
  • TABLE 43: NORTH AMERICA: MYCOPLASMA TESTING MARKET SIZE, BY APPLICATION, 2012-2019 (USD MILLION)
  • TABLE 44: NORTH AMERICA: MYCOPLASMA TESTING MARKET SIZE, BY END USER, 2012-2019 (USD MILLION)
  • TABLE 45: U.S.: MYCOPLASMA TESTING MARKET SIZE, BY PRODUCT, 2012-2019 (USD MILLION)
  • TABLE 46: U.S.: KITS & REAGENTS MARKET SIZE, BY TYPE, 2012-2019 (USD MILLION)
  • TABLE 47: U.S.: MYCOPLASMA TESTING MARKET SIZE, BY TECHNOLOGY, 2012-2019 (USD MILLION)
  • TABLE 48: U.S.: MYCOPLASMA TESTING MARKET SIZE, BY APPLICATION, 2012-2019 (USD MILLION)
  • TABLE 49: U.S.: MYCOPLASMA TESTING MARKET SIZE, BY END USER, 2012-2019 (USD MILLION)
  • TABLE 50: CANADA: MYCOPLASMA TESTING MARKET SIZE, BY PRODUCT, 2012-2019 (USD MILLION)
  • TABLE 51: CANADA: KITS & REAGENTS MARKET SIZE, BY TYPE, 2012-2019 (USD MILLION)
  • TABLE 52: CANADA: MYCOPLASMA TESTING MARKET SIZE, BY TECHNOLOGY, 2012-2019 (USD MILLION)
  • TABLE 53: CANADA: MYCOPLASMA TESTING MARKET SIZE, BY APPLICATION, 2012-2019 (USD MILLION)
  • TABLE 54: CANADA: MYCOPLASMA TESTING MARKET SIZE, BY END USER, 2012-2019 (USD MILLION)
  • TABLE 55: EUROPE: MYCOPLASMA TESTING MARKET SIZE, BY PRODUCT, 2012-2019 (USD MILLION)
  • TABLE 56: EUROPE: KITS & REAGENTS MARKET SIZE, BY TYPE, 2012-2019 (USD MILLION)
  • TABLE 57: EUROPE: MYCOPLASMA TESTING MARKET SIZE, BY TECHNOLOGY, 2012-2019 (USD MILLION)
  • TABLE 58: EUROPE: MYCOPLASMA TESTING MARKET SIZE, BY APPLICATION, 2012-2019 (USD MILLION)
  • TABLE 59: EUROPE: MYCOPLASMA TESTING MARKET SIZE, BY END USER, 2012-2019 (USD MILLION)
  • TABLE 60: ASIA: MYCOPLASMA TESTING MARKET SIZE, BY PRODUCT, 2012-2019 (USD MILLION)
  • TABLE 61: ASIA: KITS & REAGENTS MARKET SIZE, BY TYPE, 2012-2019 (USD MILLION)
  • TABLE 62: ASIA: MYCOPLASMA TESTING MARKET SIZE, BY TECHNOLOGY, 2012-2019 (USD MILLION)
  • TABLE 63: ASIA: MYCOPLASMA TESTING MARKET SIZE, BY APPLICATION, 2012-2019 (USD MILLION)
  • TABLE 64: ASIA: MYCOPLASMA TESTING MARKET SIZE, BY END USER, 2012-2019 (USD MILLION)
  • TABLE 65: ROW: MYCOPLASMA TESTING MARKET SIZE, BY PRODUCT, 2012-2019 (USD MILLION)
  • TABLE 66: ROW: KITS & REAGENTS MARKET SIZE, BY TYPE, 2012-2019 (USD MILLION)
  • TABLE 67: ROW: MYCOPLASMA TESTING MARKET SIZE, BY TECHNOLOGY, 2012-2019 (USD MILLION)
  • TABLE 68: ROW: MYCOPLASMA TESTING MARKET SIZE, BY APPLICATION, 2012-2019 (USD MILLION)
  • TABLE 69: ROW: MYCOPLASMA TESTING MARKET SIZE, BY END USER, 2012-2019 (USD MILLION)
  • TABLE 70: AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS, 2011-2015
  • TABLE 71: EXPANSIONS, 2011-2015
  • TABLE 72: ACQUISITIONS, 2011-2015
  • TABLE 73: NEW PRODUCT & SERVICE LAUNCHES, 2011-2015
  • TABLE 74: OTHER DEVELOPMENTS, 2011-2015

LIST OF FIGURES

  • FIGURE 1: GLOBAL MYCOPLASMA TESTING MARKET
  • FIGURE 2: RESEARCH DESIGN
  • FIGURE 3: MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
  • FIGURE 4: MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 5: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 6: DATA TRIANGULATION METHODOLOGY
  • FIGURE 7: MYCOPLASMA TESTING MARKET SIZE, BY PRODUCT, 2014 (USD MILLION)
  • FIGURE 8: MYCOPLASMA TESTING MARKET SIZE, KITS & REAGENTS BY TYPE, 2014 (USD MILLION)
  • FIGURE 9: MYCOPLASMA TESTING MARKET SIZE, BY TECHNOLOGY, 2014 (USD MILLION)
  • FIGURE 10: MYCOPLASMA TESTING MARKET SIZE, BY APPLICATION, 2014 (USD MILLION)
  • FIGURE 11: MYCOPLASMA TESTING MARKET SIZE, BY END USER, 2014 (USD MILLION)
  • FIGURE 12: MYCOPLASMA TESTING MARKET SIZE, BY GEOGRAPHY, 2014 (USD MILLION)
  • FIGURE 13: INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES AND PHARMACEUTICAL OUTSOURCING ARE IMPORTANT GROWTH DRIVERS
  • FIGURE 14: KITS & REAGENTS TO DOMINATE THE MYCOPLASMA TESTING MARKET
  • FIGURE 15: ASIA TO GROW AT THE HIGHEST RATE DURING THE FORECAST PERIOD
  • FIGURE 16: ASIAN MARKET SHOWCASES LUCRATIVE GROWTH OPPORTUNITIES IN THE FORECAST PERIOD
  • FIGURE 17: MARKET SEGMENTATION: BY PRODUCT
  • FIGURE 18: MARKET SEGMENTATION: BY TECHNOLOGY
  • FIGURE 19: MARKET SEGMENTATION: BY APPLICATION
  • FIGURE 20: MARKET SEGMENTATION: BY END USER
  • FIGURE 21: GROWTH IN PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRIES WILL DRIVE THE MYCOPLASMA TESTING MARKET
  • FIGURE 22: INCREASING R&D INVESTMENTS IS AN IMPORTANT DRIVER FOR THE MYCOPLASMA TESTING MARKET
  • FIGURE 23: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 24: MAJOR PLAYERS ADOPTED THE INORGANIC GROWTH STRATEGY OF AGREEMENTS, COLLABORATIONS, & PARTNERSHIPS BETWEEN 2011 & 2014
  • FIGURE 25: SUPPLY CHAIN ANALYSIS
  • FIGURE 26: MYCOPLASMA TESTING MARKET, BY PRODUCT
  • FIGURE 27: KITS & REAGENTS COMMANDED THE LARGEST SHARE OF THE MYCOPLASMA TESTING MARKET IN 2014
  • FIGURE 28: MYCOPLASMA TESTING KITS & REAGENTS MARKET, BY TYPE
  • FIGURE 29: PCR ASSAYS COMMANDED THE LARGEST SHARE OF KITS & REAGENTS IN 2014
  • FIGURE 30: ASIA WILL BE THE FASTEST-GROWING SEGMENT OF THE KITS & REAGENTS MARKET IN THE FORECAST PERIOD
  • FIGURE 31: NORTH AMERICA COMMANDED THE LARGEST SHARE OF THE PCR ASSAYS SEGMENT IN 2014
  • FIGURE 32: ASIA TO BE THE FASTEST-GROWING SEGMENT OF THE NUCLEIC ACID DETECTION KITS MARKET IN THE FORECAST PERIOD
  • FIGURE 33: ASIA TO BE THE FASTEST-GROWING SEGMENT OF THE STAINS MARKET IN THE FORECAST PERIOD
  • FIGURE 34: NORTH AMERICA COMMANDED THE LARGEST SHARE OF THE STANDARDS & CONTROLS SEGMENT IN 2014
  • FIGURE 35: ASIA TO BE THE FASTEST-GROWING SEGMENT OF THE OTHER KITS & REAGENTS MARKET IN THE FORECAST PERIOD
  • FIGURE 36: NORTH AMERICA COMMANDED THE LARGEST SHARE OF THE INSTRUMENTS SEGMENT IN 2014
  • FIGURE 37: ASIA TO BE THE FASTEST-GROWING SEGMENT OF THE SERVICES MARKET IN THE FORECAST PERIOD
  • FIGURE 38: GLOBAL MYCOPLASMA TESTING MARKET, BY TECHNOLOGY
  • FIGURE 39: PCR WILL BE THE LARGEST APPLICATION SEGMENT IN THE GLOBAL MYCOPLASMA TESTING MARKET
  • FIGURE 40: NORTH AMERICA ACCOUNTED FOR THE LARGEST SHARE OF THE PCR TECHNOLOGY SEGMENT IN 2014
  • FIGURE 41: NORTH AMERICA ACCOUNTED FOR THE LARGEST SHARE OF THE ELISA TECHNOLOGY SEGMENT IN 2014
  • FIGURE 42: NORTH AMERICA ACCOUNTED FOR THE LARGEST SHARE OF THE DIRECT ASSAY TECHNOLOGY SEGMENT IN 2014
  • FIGURE 43: NORTH AMERICA ACCOUNTED FOR THE LARGEST SHARE OF THE INDIRECT ASSAY TECHNOLOGY SEGMENT IN 2014
  • FIGURE 44: NORTH AMERICA ACCOUNTED FOR THE LARGEST SHARE OF THE MICROBIAL CULTURE TECHNIQUES SEGMENT IN 2014
  • FIGURE 45: NORTH AMERICA ACCOUNTED FOR THE LARGEST SHARE OF THE ENZYMATIC METHODS SEGMENT IN 2014
  • FIGURE 46: MYCOPLASMA TESTING MARKET SEGMENTATION, BY APPLICATION
  • FIGURE 47: CELL LINE TESTING WILL BE THE FASTEST-GROWING APPLICATION SEGMENT
  • FIGURE 48: NORTH AMERICA COMMANDED THE LARGEST SHARE OF THE CELL LINE TESTING SEGMENT IN 2014
  • FIGURE 49: NORTH AMERICA DOMINATED THE VIRUS TESTING SEGMENT IN 2014
  • FIGURE 50: ASIAN MARKET FOR THE END OF PRODUCTION CELLS TESTING MARKET TO GROW AT THE HIGHEST CAGR
  • FIGURE 51: NORTH AMERICA HELD THE LARGEST SHARE OF THE OTHER APPLICATIONS SEGMENT IN 2014
  • FIGURE 52: MYCOPLASMA TESTING MARKET SEGMENTATION, BY END USER
  • FIGURE 53: MYCOPLASMA TESTING MARKET SIZE, BY END USER, 2014 VS. 2019 (USD MILLION)
  • FIGURE 54: LARGE NUMBER OF GRANTED PATENTS ENHANCING THE GROWTH OF PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT
  • FIGURE 55: NORTH AMERICA COMMANDED THE LARGEST SHARE OF THE PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES SEGMENT IN 2014
  • FIGURE 56: NORTH AMERICA COMMANDED THE LARGEST SHARE OF THE CONTRACT RESEARCH ORGANIZATIONS END-USER SEGMENT IN 2014
  • FIGURE 57: PUBLIC SECTOR RESEARCH FUNDING IS DRIVING THE GROWTH OF THE ACADEMIC RESEARCH INSTITUTES SEGMENT
  • FIGURE 58: ASIAN MYCOPLASMA TESTING MARKET FOR ACADEMIC RESEARCH INSTITUTES TO GROW AT HIGHEST RATE IN THE FORECAST PERIOD
  • FIGURE 59: NORTH AMERICA COMMANDED THE LARGEST SHARE OF THE CELL BANKS SEGMENT IN 2014
  • FIGURE 60: ASIAN MYCOPLASMA TESTING MARKET FOR OTHER END USERS TO GROW AT HIGHEST RATE IN THE FORECAST PERIOD
  • FIGURE 61: GEOGRAPHIC SNAPSHOT (2014)
  • FIGURE 62: ASIA TO GROW AT THE HIGHEST RATE DURING THE FORECAST PERIOD
  • FIGURE 63: U.S. TO GROW AT A HIGHER RATE IN THE FORECAST PERIOD
  • FIGURE 64: NORTH AMERICAN MYCOPLASMA TESTING MARKET SNAPSHOT (2014-2019): AVAILABILITY OF RESEARCH FUNDING DRIVING MARKET GROWTH
  • FIGURE 65: KITS & REAGENTS ESTIMATED TO BE THE LARGEST PRODUCT SEGMENT IN THE MARKET IN 2014
  • FIGURE 66: NORTH AMERICA: PCR ASSAYS SEGMENT TO GROW AT THE HIGHEST CAGR FROM 2014 TO 2019
  • FIGURE 67: PCR WILL BE THE LARGEST TECHNOLOGY SEGMENT IN MYCOPLASMA TESTING MARKET IN NORTH AMERICA
  • FIGURE 68: NORTH AMERICA: MYCOPLASMA TESTING MARKET SIZE, BY APPLICATION, 2014 VS. 2019
  • FIGURE 69: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO ACCOUNT FOR THE LARGEST SHARE OF THE MYCOPLASMA TESTING END-USERS MARKET IN NORTH AMERICA
  • FIGURE 70: KITS & REAGENTS, THE LARGEST PRODUCT SEGMENT IN THE U.S. IN 2014
  • FIGURE 71: U.S.: PCR ASSAYS TO GROW AT THE HIGHEST CAGR FROM 2014 TO 2019
  • FIGURE 72: PCR WILL BE THE LARGEST TECHNOLOGY SEGMENT IN THE MYCOPLASMA TESTING MARKET IN THE U.S.
  • FIGURE 73: U.S.: MYCOPLASMA TESTING MARKET SIZE, BY APPLICATION, 2014 VS. 2019
  • FIGURE 74: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO ACCOUNT FOR THE LARGEST SHARE OF THE MYCOPLASMA TESTING END-USERS MARKET IN THE U.S.
  • FIGURE 75: KITS & REAGENTS, THE LARGEST PRODUCT SEGMENT IN CANADA IN 2014
  • FIGURE 76: CANADA: PCR ASSAYS TO GROW AT THE HIGHEST CAGR FROM 2014 TO 2019
  • FIGURE 77: PCR WILL BE THE LARGEST TECHNOLOGY SEGMENT OF MYCOPLASMA TESTING MARKET IN CANADA
  • FIGURE 78: CANADA: MYCOPLASMA TESTING MARKET SIZE, BY APPLICATION, 2014 VS. 2019
  • FIGURE 79: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO ACCOUNT FOR THE LARGEST SHARE OF THE MYCOPLASMA TESTING END-USERS MARKET IN CANADA
  • FIGURE 80: KITS & REAGENTS, THE LARGEST PRODUCT SEGMENT IN THE EUROPEAN MARKET IN 2014
  • FIGURE 81: PCR ASSAYS DOMINATED KITS & REAGENTS MARKET IN EUROPE IN 2014
  • FIGURE 82: PCR WILL BE THE LARGEST TECHNOLOGY SEGMENT IN THE MYCOPLASMA TESTING MARKET IN EUROPE
  • FIGURE 83: EUROPE: MYCOPLASMA TESTING MARKET SIZE, BY APPLICATION, 2014 VS. 2019
  • FIGURE 84: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO ACCOUNT FOR THE LARGEST SHARE OF THE MYCOPLASMA TESTING END-USERS MARKET IN EUROPE
  • FIGURE 85: ASIA: MARKET SNAPSHOT
  • FIGURE 86: KITS & REAGENTS, THE LARGEST PRODUCT SEGMENT IN ASIA IN 2014
  • FIGURE 87: ASIA: PCR ASSAYS TO GROW AT THE HIGHEST CAGR FROM 2014 TO 2019
  • FIGURE 88: PCR WILL BE THE LARGEST TECHNOLOGY SEGMENT IN THE ASIAN MYCOPLASMA TESTING MARKET
  • FIGURE 89: ASIA: MYCOPLASMA TESTING MARKET SIZE, BY APPLICATION, 2014 VS. 2019
  • FIGURE 90: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO ACCOUNT FOR THE LARGEST SHARE OF THE MYCOPLASMA TESTING END-USERS MARKET IN ASIA
  • FIGURE 91: KITS & REAGENTS, THE LARGEST PRODUCT SEGMENT IN ROW IN 2014
  • FIGURE 92: ROW: PCR ASSAYS TO GROW AT THE HIGHEST CAGR FROM 2014 TO 2019
  • FIGURE 93: PCR WILL BE THE LARGEST TECHNOLOGY SEGMENT IN THE MYCOPLASMA TESTING MARKET IN ROW
  • FIGURE 94: ROW: MYCOPLASMA TESTING MARKET SIZE, BY APPLICATION, 2014 VS. 2019
  • FIGURE 95: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO ACCOUNT FOR THE LARGEST SHARE OF THE MYCOPLASMA TESTING END-USERS MARKET IN ROW
  • FIGURE 96: AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS ARE KEY STRATEGIES ADOPTED BY PLAYERS IN THE MYCOPLASMA TESTING MARKET
  • FIGURE 97: GLOBAL MYCOPLASMA TESTING MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2014
  • FIGURE 98: COMPETITIVE SITUATION AND TRENDS: AGREEMENTS, COLLABORATIONS & PARTNERSHIPS ARE THE KEY GROWTH STRATEGIES
  • FIGURE 99: FINANCIAL PERFORMANCES OF THE LEADING MARKET PLAYERS
  • FIGURE 100: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT
  • FIGURE 101: LONZA GROUP LTD.: COMPANY SNAPSHOT
  • FIGURE 102: MERCK KGAA: COMPANY SNAPSHOT
  • FIGURE 103: SIGMA-ALDRICH CORPORATION: COMPANY SNAPSHOT
  • FIGURE 104: THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT
Back to Top